Companies and initiatives working with xCures to improve health outcomes
Aetion®
xCures and Aetion® have partnered to create rich, fully longitudinal clinical oncology data using real-world evidence (RWE) development to bring the patient front and center in oncology research.
AWS Marketplace
xCures partners with AWS Marketplace to offer its platform as a clinical data extraction service, and enhance the security and scalability of the platform.
Critical Path Institute
The Critical Path Institute partnered with xCures to quickly abstract and structure clinical data to support drug repurposing studies in rare cancers.
Novocure
Novocure has partnered with xCures to better understand the links between quality of life and treatment decisions, disease characteristics, and other factors for patients diagnosed with glioblastoma. (Publication: 2022)
PanCAN
PanCAN partnered with xCures to give their researchers and grantees access to xCures’ de-identified data to improve research, and help their patients find the right treatments.
BioMed Valley Discoveries
BioMed Valley Discoveries partnered with xCures to offer expanded access to ulixertinib, an ERK1/2 inhibitor for patients with advanced solid tumors no longer responding to standard of care. (Publications: 2022, 2022)
Visit BioMed Valley Discoveries
Cellworks
Cellworks partnered with xCures to advance predictive algorithms based on molecular systems biology and personalize oncology through multi-omic therapy biosimulation.
Cancer Commons
Cancer Commons partners with xCures to provide a highly customized and personal experience for advanced cancer patients in need of treatment options. (Publications: 2020, 2021, 2022)
COLONTOWN
COLONTOWN collaborates with xCures to create a comprehensive precision medicine resource for COLONTOWN University.
CureGM1
CureGM1 is partnering with xCures to develop a special rare disease protocol for GM1 gangliosidosis and develop a new rare disease electronic natural history study.
CureMatch
xCures partnered with CureMatch to leverage their proprietary curated knowledge base and help match patients to the best therapy options based on the unique molecular makeup of their tumor.
CureScience
xCures’ partnership with CureScience serves to better identify specific patients and patient populations that may benefit from a particular test or treatment.
DIPG/DMG Research Funding Alliance
DDRFA partnered with xCures to streamline DMG & DIPG research and enhance patient care by centralizing the collection and analysis of anonymized DMG patient data.
Visit DIPG/DMG Research Funding Alliance
DTRA
xCures is a founding member of a historic alliance of close to a hundred life sciences and healthcare organizations that seek to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.
EHE Foundation
The EHE Foundation partnered with xCures to set up a research registry for patients with epithelioid hemangioendothelioma (EHE)
End Brain Cancer Initiative
The End Brain Cancer Initiative (EBCI) has partnered with xCures to help patients easily and quickly access their electronic medical records from every care site.
Visit End Brain Cancer Initiative
Endeavor
Endeavor partnered with xCures to help screen and enroll patients who might be eligible for their PTCH1 clinical trial
Faeth
Faeth partnered with xCures to launch a medical food clinical trial for treatment of patients with recent pancreatic adenocarcinoma or advanced PDAC and evaluate tolerability and satisfaction with the diet
Fibro Fighters
The FibroFighters Foundation is collaborating with xCures on an Observational Research Study to advance knowledge about FLHCC across the country. FLHCC is a rare cancer primarily affecting adolescents and young adults. Enroll Here (Publication: 2023)
Fibrolamellar Cancer Foundation
The Fibrolamellar Cancer Foundation has partnered with xCures to drive fibrolamellar carcinoma (FLC) research and find treatment options for patients with FLC, a rare and often-fatal disease.
Visit Fibrolamellar Cancer Foundation
Genome Medical
Genome Medical and xCures have joined forces to provide genetic counselors access to xCures’ care summaries for patients based on electronic medical records from across the healthcare ecosystem.
Imaging Biometrics
xCures is working together with Imaging Biometrics on their expanded access program and use the xCures platform to quickly screen brain tumor patients for eligibility and collect clinical data
Institute of Systems Biology
The Institute of Systems Biology has partnered with xCures to develop innovative clinical trials to advance systems biology algorithms in glioblastoma and multiple myeloma. (Publication: 2022)
Visit Institute of Systems Biology
Kidney Cancer Association
The Kidney Cancer Association partnered with xCures to advance kidney cancer research and bring trial participation and treatment opportunities to kidney cancer patients.
Visit Kidney Cancer Association
Layer Health
xCures partners with AI company Layer Health to leverage Layer Health’s large language models, trained and validated on xCures’ data, for rapid structuring of clinical notes in the xCures Platform.
mProbe
mProbe partnered with xCures to leverage their targeted proteomics platform for profiling individual patients’ cancer tissues for actionable drug targets.
Musella Foundation
The Musella Foundation partnered with xCures and Cancer Commons to ensure that brain cancer patients get fast access to promising treatment options. (Publications: 2023, 2023)
Oblato
Oblato partnered with xCures to offer OKN-007 through an expanded access program for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of diffuse intrinsic pontine glioma (DIPG)
Oncoceutics
Oncoceutics collaborated with xCures and Cancer Commons to implement an Expanded Access program for ONC201. (Publication: 2022)
Patient Record Scorecard
xCures is a supporter of the Ciitizen Patient Record Scorecard that shows how medical record providers comply with the HIPAA Right of Access based on patient requests.
Visit Patient Record Scorecard
POETIC
xCures collaborates with POETIC, a non-profit organization that manages pediatric oncology early phase trials, to get children, adolescents, and young adults with cancer enrolled in expanded access programs of promising therapies. Learn More
Prognos Health
Prognos Health and xCures partnered to enable access to real-world oncology datasets and use continuous learning from every patient’s journey to drive insights and improve outcomes
SonALAsense
SonALAsense partnered with xCures to set up a Natural History study for DIPG and DMG, accelerating DIGP/DMG research, and ending randomization in pediatric clinical trials.